MariMed (OTCMKTS:MRMD – Get Free Report) is expected to announce its Q2 2026 results after the market closes on Wednesday, August 12th. Analysts expect MariMed to post earnings of ($0.01) per share and revenue of $39.80 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:00 AM ET.
MariMed (OTCMKTS:MRMD – Get Free Report) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). The company had revenue of $39.48 million for the quarter, compared to analysts’ expectations of $38.75 million. MariMed had a negative return on equity of 5.00% and a negative net margin of 7.82%.
MariMed Stock Performance
MRMD opened at $0.06 on Tuesday. The firm has a market cap of $26.04 million, a PE ratio of -2.16 and a beta of 1.33. The company has a quick ratio of 0.34, a current ratio of 0.95 and a debt-to-equity ratio of 1.67. The business has a fifty day simple moving average of $0.07 and a 200-day simple moving average of $0.08. MariMed has a fifty-two week low of $0.06 and a fifty-two week high of $0.23.
MariMed Company Profile
MariMed Inc is a multi‐state cannabis company focused on the development, ownership and operation of regulated facilities for the medical and adult‐use cannabis markets. Headquartered in New Bedford, Massachusetts, the company cultivates, processes and dispenses cannabis through an integrated business model that encompasses cultivation, formulation, manufacturing and retail operations. MariMed operates under its own licensed brands and through strategic partnerships to expand its presence across the United States.
The company’s product portfolio includes branded flower, pre‐rolls, vaporizer cartridges, tinctures, edibles and topicals designed to meet a range of consumer and patient needs.
See Also
- Five stocks we like better than MariMed
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for MariMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MariMed and related companies with MarketBeat.com's FREE daily email newsletter.
